Casirati, Gabriele http://orcid.org/0000-0003-1925-1195
Cosentino, Andrea
Mucci, Adele
Salah Mahmoud, Mohammed http://orcid.org/0000-0002-9190-6590
Ugarte Zabala, Iratxe
Zeng, Jing
Ficarro, Scott B.
Klatt, Denise
Brendel, Christian
Rambaldi, Alessandro http://orcid.org/0000-0002-3739-7502
Ritz, Jerome http://orcid.org/0000-0001-5526-4669
Marto, Jarrod A. http://orcid.org/0000-0003-2086-1134
Pellin, Danilo http://orcid.org/0000-0002-2647-0508
Bauer, Daniel E.
Armstrong, Scott A. http://orcid.org/0000-0002-9099-4728
Genovese, Pietro http://orcid.org/0000-0001-9507-9003
Article History
Received: 17 September 2022
Accepted: 28 July 2023
First Online: 30 August 2023
Competing interests
: G.C. and P.G. are listed as inventors on patent applications related to this work that are owned and managed by the Boston Children’s Hospital and Dana-Farber Cancer Institute. S.A.A. has been a consultant and/or shareholder for Neomorph Inc, Imago Biosciences, Cyteir Therapeutics, C4 Therapeutics, Nimbus Therapeutics and Accent Therapeutics. S.A.A. has received research support from Janssen and Syndax. S.A.A. is named as an inventor on a patent application related to MENIN inhibition WO/2017/132398A1. J.A.M. is a founder, equity holder and advisor to Entact Bio, serves on the scientific advisory board of 908 Devices and receives sponsored research funding from Vertex, AstraZeneca, Taiho, Springworks and TUO Therapeutics. The other authors declare no competing interests.